MAXCYTE INC
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
MXCT$1.13-13.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Unaudited Condensed Consolidated Statements of Cash Flow****s
(in thousands)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · Nine Months Ended September 30, · | |||||||
| · · 2024 · 2023 · | |||||||
| Cash flows from operating activities: · · | |||||||
| Net loss | | $(30,458) | | $(32,645) | | ||
| | | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | ||
| Depreciation and amortization | | 3,258 | | 3,069 | | ||
| Non-cash lease expense | | | 353 | | | 286 | |
| Net book value of consigned equipment sold | | 35 | | 80 | | ||
| Loss on disposal of fixed assets | | | 462 | | | 2 | |
| Stock-based compensation | | 9,949 | | 10,405 | | ||
| Credit loss (recovery) expense | | | (130) | | | 221 | |
| Change in excess/obsolete inventory reserve | | | 834 | | | — | |
| Amortization of discounts on investments | | (5,052) | | (5,123) | | ||
| | | | | | | | |
| Changes in operating assets and liabilities: | | | | | | ||
| Accounts receivable | | 1,348 | | 3,571 | | ||
| Accounts receivable - TIA | | | — | | | 1,912 | |
| Inventory | | 835 | | (4,088) | | ||
| Prepaid expense and other current assets | | (225) | | (924) | | ||
| Other assets | | (732) | | 190 | | ||
| Accounts payable, accrued expenses and other | | (1,420) | | 1,520 | | ||
| Operating lease liability | | (424) | | (13) | | ||
| Deferred revenue | | 1,584 | | (1,127) | | ||
| Other liabilities | | (6) | | (3) | | ||
| Net cash used in operating activities | | (19,789) | | (22,667) | | ||
| | | | | | | | |
| Cash flows from investing activities: | | | | ||||
| Purchases of investments | | (118,339) | | | (185,621) | | |
| Maturities of investments | | 128,440 | | | 247,520 | | |
| Purchases of property and equipment | | (1,504) | | | (2,785) | | |
| Proceeds from sale of equipment | | | — | | | 9 | |
| Net cash provided by investing activities | | 8,597 | | 59,123 | | ||
| | | | | | | | |
| Cash flows from financing activities: | | | | ||||
| Proceeds from exercise of stock options | | 1,379 | | | 1,650 | | |
| Proceeds from issuance of common stock under employee stock purchase plan | | | 265 | | | — | |
| Net cash provided by financing activities | | 1,644 | | 1,650 | | ||
| Net (decrease) increase in cash and cash equivalents | | (9,548) | | 38,106 | | ||
| Cash and cash equivalents, beginning of period | | 46,506 | | 11,064 | | ||
| Cash and cash equivalents, end of period | | $36,958 | | $49,170 | | ||
| | | | | | | | |
| Supplemental disclosure of non-cash investing and financing activities: | | | | | |||
| Property and equipment purchases included in accounts payable and accrued expenses | | $35 | | $287 | | ||
MaxCyte, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except par value, share and per share amounts)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.